Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-319 in Refractory/Relapsed or MRD-Positive B-ALL
NCT07371533Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Open-label trial of A-319 in Acute B-cell lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Shanxi Bethune Hospital. Primary endpoints: Safety Analysis and Dose-Limiting Toxicity. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
A-319
03
Conditions
Acute B-cell lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07371533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371533.